Race, Ethnicity, and Diffuse Parenchymal Lung Disease

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
David J. Lederer, M.D., Columbia University
ClinicalTrials.gov Identifier:
First received: March 27, 2007
Last updated: April 20, 2015
Last verified: April 2015
The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.

Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Diffuse Parenchymal Lung Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Determinants of Outcome in Diffuse Parenchymal Lung Disease

Resource links provided by NLM:

Further study details as provided by Columbia University:

Biospecimen Retention:   Samples With DNA
Plasma/serum, DNA, and circulating cells and endothelial microparticles will be collected and processed.

Enrollment: 565
Study Start Date: July 2006
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Detailed Description:
It is well known that both socioeconomic and biological factors may contribute to race- and ethnicity-based health disparities. Black and Hispanic Americans have worse access to healthcare services and tend to receive care from physicians who cannot themselves access the same services for their patients that physicians who care for white patients can. These factors may play important roles in the development and maintenance of health disparities. In addition, biological differences may contribute to disparities. We propose to identify factors that explain survival disparities in a group of lung diseases called diffuse parenchymal lung diseases (DPLDs), including a severe form of DPLD called idiopathic pulmonary fibrosis (IPF). We will follow patients with DPLD at our center and measure both social and biological factors to try to identify the factors that lead to survival disparities between races. Results of this study will be used to design clinical trials aimed at reducing these disparities.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diffuse parenchymal lung disease

Inclusion Criteria:

  • Diagnosis of IPF or other DPLD according to ATS criteria
  • Signed informed consent

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00453713

United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: David J Lederer, M.D. Columbia University
  More Information

No publications provided

Responsible Party: David J. Lederer, M.D., Irving Assistant Professor of Medicine (in Pediatrics), Columbia University
ClinicalTrials.gov Identifier: NCT00453713     History of Changes
Other Study ID Numbers: AAAB8771, K23HL086714
Study First Received: March 27, 2007
Last Updated: April 20, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
Idiopathic pulmonary fibrosis
Interstitial lung disease
Diffuse parenchymal lung disease
Health disparities

Additional relevant MeSH terms:
Idiopathic Interstitial Pneumonias
Idiopathic Pulmonary Fibrosis
Lung Diseases
Lung Diseases, Interstitial
Pulmonary Fibrosis
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 27, 2015